Literature DB >> 27034492

Complete Genome Sequence of Mycobacterium bovis Strain BCG-1 (Russia).

Evgeniya A Sotnikova1, Egor A Shitikov2, Maja V Malakhova2, Elena S Kostryukova2, Elena N Ilina2, Alena V Atrasheuskaya3, Georgy M Ignatyev3, Nataliya V Vinokurova3, Vyacheslav Y Gorbachyov3.   

Abstract

Mycobacterium bovisBCG (Bacille Calmette-Guérin) is a vaccine strain used for protection against tuberculosis. Here, we announce the complete genome sequence ofM. bovisstrain BCG-1 (Russia). Extensive use of this strain necessitates the study of its genome stability by comparative analysis.
Copyright © 2016 Sotnikova et al.

Entities:  

Year:  2016        PMID: 27034492      PMCID: PMC4816620          DOI: 10.1128/genomeA.00182-16

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, was developed by Albert Calmette and Camille Guerin in 1921 as a vaccine against tuberculosis. As a result of distributing BCG throughout the world, daughter strains appeared, and one of the first strains was BCG Russia (1). It belongs to early strains and is one of the most widely used strains in the world (2). Though most of the described differences among BCG strains refer to the period before the worldwide use of lyophilized vaccine, Wada et al. (3) have shown that mutations in vaccine strains obtained by various vaccine manufacturers from a single cell source over time reach detectable levels. Because of that, whole-genome sequencing and comparison of all BCG Russia strains are extremely important. Here, we report the complete genome sequence of M. bovis BCG-1, isolated from a working seed lot used by NPO Microgen (Russia) for vaccine production. Genomic DNA was isolated according to van Embden et al (4). A whole-genome shotgun library, prepared with a GS FLX Titanium rapid library preparation it (Roche 454 Life Science, USA), was sequenced using the GS FLX sequencer (Roche 454 Life Science, USA). The obtained 369,059 reads (245,806,603 nucleotides [nt]) were used for de novo assembly with GS De Novo assembler version 2.9, resulting in 81 large contigs. Then, a mate-pair library with insert sizes of 2 to 3 kb was sequenced with the Ion Torrent PGM sequencer (Applied Biosystems, USA); 546,890 reads were obtained (114,344,250 nt), which were used for scaffolding. Eleven scaffolds were generated by SSPASE software (5). The complete genome sequence of M. bovis BCG-1 comprised one circular chromosome comprising 4,370,705 bp with an average GC content of 65.60%. Annotation was generated with the NCBI Prokaryotic Genome Annotation Pipeline. A total of 4,078 genes were predicted. Three rRNAs and 45 tRNAs were identified in the genome. To confirm that the sequenced genome is a strain of BCG Russia, which was previously described, characteristics of the strain were analyzed. The following previously described features of BCG Russia were found: DU2 type I (6), 2 copies of IS6110 (7), and RDRussia (8). A single-nucleotide insertion in the recA (9) gene was not found.

Nucleotide sequence accession numbers.

The genome sequence of M. bovis strain BCG-1 (Russia) was deposited in GenBank under the accession number CP013741. The version described in this paper is the first version, CP013741.1.
  9 in total

1.  The in vitro evolution of BCG vaccines.

Authors:  Serge Mostowy; Anthony G Tsolaki; Peter M Small; Marcel A Behr
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

2.  Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains.

Authors:  N G Fomukong; J W Dale; T W Osborn; J M Grange
Journal:  J Appl Bacteriol       Date:  1992-02

3.  Scaffolding pre-assembled contigs using SSPACE.

Authors:  Marten Boetzer; Christiaan V Henkel; Hans J Jansen; Derek Butler; Walter Pirovano
Journal:  Bioinformatics       Date:  2010-12-12       Impact factor: 6.937

4.  Genome plasticity of BCG and impact on vaccine efficacy.

Authors:  Roland Brosch; Stephen V Gordon; Thierry Garnier; Karin Eiglmeier; Wafa Frigui; Philippe Valenti; Sandrine Dos Santos; Stéphanie Duthoy; Céline Lacroix; Carmen Garcia-Pelayo; Jacqueline K Inwald; Paul Golby; Javier Nuñez Garcia; R Glyn Hewinson; Marcel A Behr; Michael A Quail; Carol Churcher; Bart G Barrell; Julian Parkhill; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  A historical and molecular phylogeny of BCG strains.

Authors:  M A Behr; P M Small
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

Review 7.  Influence of BCG vaccine strain on the immune response and protection against tuberculosis.

Authors:  Nicole Ritz; Willem A Hanekom; Roy Robins-Browne; Warwick J Britton; Nigel Curtis
Journal:  FEMS Microbiol Rev       Date:  2008-07-09       Impact factor: 16.408

8.  Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant.

Authors:  Peter M Keller; Erik C Böttger; Peter Sander
Journal:  BMC Microbiol       Date:  2008-07-17       Impact factor: 3.605

9.  Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172.

Authors:  Takayuki Wada; Fumito Maruyama; Tomotada Iwamoto; Shinji Maeda; Taro Yamamoto; Ichiro Nakagawa; Saburo Yamamoto; Naoya Ohara
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

  9 in total
  7 in total

1.  Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscleinvasive bladder cancer? The jury is still out but the answer is likely no.

Authors:  Guan Hee Tan; Cynthia Kuk; Alexandre R Zlotta
Journal:  Can Urol Assoc J       Date:  2019-07-23       Impact factor: 1.862

2.  Mosaic structure of Mycobacterium bovis BCG genomes as a representation of phage sequences' mobility.

Authors:  Olga L Voronina; Marina S Kunda; Ekaterina I Aksenova; Andrey N Semenov; Natalia N Ryzhova; Vladimir G Lunin; Alexandr L Gintsburg
Journal:  BMC Genomics       Date:  2016-12-28       Impact factor: 3.969

3.  Proteomics for the Investigation of Mycobacteria.

Authors:  J A Bespyatykh; E A Shitikov; E N Ilina
Journal:  Acta Naturae       Date:  2017 Jan-Mar       Impact factor: 1.845

4.  Newly sequenced genomes of four Bacillus Calmette Guerin vaccines.

Authors:  Maria Carolina Sisco; Marlei Gomés Silva; Beatriz Lopez; Claudia Arguelles; Leila Mendonça-Lima; Jacobus H de Waard; Rafael Silva Duarte; Philip Noel Suffys
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-05-11       Impact factor: 2.743

5.  Phenotypic and Genotypic Drug Susceptibility Assessment of Mycobacterium bovis Bacillus Calmette-Guérin Clinical Strains.

Authors:  Maria Carolina Sisco; Marlei Gomes da Silva; Luciana Distasio de Carvalho; Carlos Eduardo Dias Campos; Paulo Cesar De Souza Caldas; Beatriz Lopez; Claudia Argüelles; Ana Carolina Carvalho; Jacobus de Waard; Philip Suffys; Rafael Silva Duarte
Journal:  Infect Drug Resist       Date:  2021-02-05       Impact factor: 4.003

6.  First insight into the whole-genome sequence variations in Mycobacterium bovis BCG-1 (Russia) vaccine seed lots and their progeny clinical isolates from children with BCG-induced adverse events.

Authors:  Olga Narvskaya; Daria Starkova; Diana Levi; Natalia Alexandrova; Vladimir Molchanov; Ekaterina Chernyaeva; Anna Vyazovaya; Alexander Mushkin; Viacheslav Zhuravlev; Natalia Solovieva; Boris Vishnevskiy; Igor Mokrousov
Journal:  BMC Genomics       Date:  2020-08-18       Impact factor: 3.969

7.  Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia.

Authors:  Stefan Panaiotov; Yordan Hodzhev; Vladimir Tolchkov; Borislava Tsafarova; Alexander Mihailov; Tzvetelina Stefanova
Journal:  Vaccines (Basel)       Date:  2021-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.